Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 3/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070761 | 0.80 | GABRA5 (0.44) | LDHAHPGDSRXFP1NPC1GABRA5 | |
| SCHEMBL31188400 | 0.79 | RXFP1 (0.47) | LDHARXFP1NPC1CA12CA1 | |
| SCHEMBL5223307 | 0.79 | GRM5 (0.46) | LDHA | |
| SCHEMBL30812042 | 0.77 | CA12 (0.43) | HPGDSGABRA5GABRA1GABRG2GABRB3 | |
| SCHEMBL1542758 | 0.77 | LDHA (0.80) | LDHAHPGDSRXFP1NPC1GABRA5 | |
| SCHEMBL646488 | 0.77 | CA12 (0.43) | HPGDSGABRA5GABRA1GABRG2GABRB3 | |
| SCHEMBL2072004 | 0.77 | FFAR2 (0.43) | LDHANPC1WNT3ARAB9ASMN1; SMN2 | |
| SCHEMBL13053992 | 0.76 | NPC1 (0.39) | LDHANPC1GABRA5GABRA1GABRG2 | |
| SCHEMBL5222442 | 0.76 | GRM5 (0.66) | — | |
| SCHEMBL603502 | 0.75 | CES2 (0.48) | GABRA5GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| EP-2129660-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | LDHA 1311/4885HPGDS 984/4885RXFP1 1934/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | LDHA 881/4885HPGDS 1073/4885RXFP1 1521/4885 |
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | LDHA 881/4885HPGDS 1073/4885RXFP1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.